WallStreetZenWallStreetZen

NASDAQ: URGN
Urogen Pharma Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for URGN

Based on 7 analysts offering 12 month price targets for Urogen Pharma Ltd

Min Forecast
$3.00-85.61%
Avg Forecast
$28.14+34.98%
Max Forecast
$47.00+125.42%

Should I buy or sell URGN stock?

Based on 7 analysts offering ratings for Urogen Pharma Ltd.

Strong Buy
Strong Buy
3 analysts 42.86%
Buy
3 analysts 42.86%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although URGN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates URGN as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their URGN stock forecasts and price targets.

URGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-27
lockedlocked$00.00+00.00%2025-10-27
lockedlocked$00.00+00.00%2025-08-19
lockedlocked$00.00+00.00%2025-06-13
lockedlocked$00.00+00.00%2025-06-13
Guggenheim
Top 3%
98
Strong BuyMaintains$15.00-28.06%2025-05-23
Goldman Sachs
Bottom 11%
11
HoldMaintains$3.00-85.61%2025-05-22

1 of 1

Forecast return on equity

Is URGN forecast to generate an efficient return?

Company
-304.46%
Industry
259.66%
Market
146.21%
URGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is URGN forecast to generate an efficient return on assets?

Company
57.12%
Industry
109.72%
URGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

URGN earnings per share forecast

What is URGN's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$3.22
Avg 2 year Forecast
-$0.83
Avg 3 year Forecast
$1.40

URGN revenue forecast

What is URGN's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$123.3M+34.22%
Avg 2 year Forecast
$268.9M+192.65%
Avg 3 year Forecast
$422.2M+359.6%
URGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

URGN revenue growth forecast

How is URGN forecast to perform vs Biotechnology companies and vs the US market?

Company
66.06%
Industry
108.79%
Market
25.21%
URGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
URGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

URGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
URGN$20.85$28.14+34.98%Strong Buy
PHAT$13.81$16.40+18.75%Buy
RAPP$26.48$35.33+33.43%Strong Buy
KURA$11.04$28.17+155.14%Buy
PROK$3.22$6.25+94.10%Strong Buy
View Top Biotech Stocks

Urogen Pharma Stock Forecast FAQ

Is Urogen Pharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: URGN) stock is to Strong Buy URGN stock.

Out of 7 analysts, 3 (42.86%) are recommending URGN as a Strong Buy, 3 (42.86%) are recommending URGN as a Buy, 1 (14.29%) are recommending URGN as a Hold, 0 (0%) are recommending URGN as a Sell, and 0 (0%) are recommending URGN as a Strong Sell.

If you're new to stock investing, here's how to buy Urogen Pharma stock.

What is URGN's earnings growth forecast for 2025-2027?

(NASDAQ: URGN) Urogen Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 27.06%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.04%.

Urogen Pharma's earnings in 2025 is -$138,431,000.On average, 10 Wall Street analysts forecast URGN's earnings for 2025 to be -$148,263,119, with the lowest URGN earnings forecast at -$155,889,292, and the highest URGN earnings forecast at -$127,809,854. On average, 10 Wall Street analysts forecast URGN's earnings for 2026 to be -$38,213,855, with the lowest URGN earnings forecast at -$98,052,105, and the highest URGN earnings forecast at $98,762,160.

In 2027, URGN is forecast to generate $64,665,700 in earnings, with the lowest earnings forecast at -$19,429,680 and the highest earnings forecast at $195,587,807.

What is URGN's revenue growth forecast for 2025-2027?

(NASDAQ: URGN) Urogen Pharma's forecast annual revenue growth rate of 66.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.79%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.21%.

Urogen Pharma's revenue in 2025 is $91,871,000.On average, 10 Wall Street analysts forecast URGN's revenue for 2025 to be $5,685,509,783, with the lowest URGN revenue forecast at $4,672,068,010, and the highest URGN revenue forecast at $6,573,078,215. On average, 10 Wall Street analysts forecast URGN's revenue for 2026 to be $12,396,449,276, with the lowest URGN revenue forecast at $10,144,100,295, and the highest URGN revenue forecast at $18,952,467,734.

In 2027, URGN is forecast to generate $19,468,410,110 in revenue, with the lowest revenue forecast at $13,753,391,559 and the highest revenue forecast at $34,196,513,183.

What is URGN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: URGN) forecast ROA is 57.12%, which is lower than the forecast US Biotechnology industry average of 109.72%.

What is URGN's Price Target?

According to 7 Wall Street analysts that have issued a 1 year URGN price target, the average URGN price target is $28.14, with the highest URGN stock price forecast at $47.00 and the lowest URGN stock price forecast at $3.00.

On average, Wall Street analysts predict that Urogen Pharma's share price could reach $28.14 by Oct 27, 2026. The average Urogen Pharma stock price prediction forecasts a potential upside of 34.98% from the current URGN share price of $20.85.

What is URGN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: URGN) Urogen Pharma's current Earnings Per Share (EPS) is -$2.98. On average, analysts forecast that URGN's EPS will be -$3.22 for 2025, with the lowest EPS forecast at -$3.38, and the highest EPS forecast at -$2.77. On average, analysts forecast that URGN's EPS will be -$0.83 for 2026, with the lowest EPS forecast at -$2.13, and the highest EPS forecast at $2.14. In 2027, URGN's EPS is forecast to hit $1.40 (min: -$0.42, max: $4.24).

What is URGN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: URGN) forecast ROE is -304.46%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.